Shire PLC (NASDAQ:SHPG) Updates FY17 Earnings Guidance
Shire PLC (NASDAQ:SHPG) issued an update on its FY17 earnings guidance on Thursday morning. The company provided earnings per share guidance of $14.80-15.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $14.85. The company issued revenue guidance of $14.9-15.3 billion, compared to the consensus revenue estimate of $15.04 billion.
Shares of Shire PLC (NASDAQ SHPG) opened at 155.91 on Friday. The firm has a market cap of $46.44 billion, a PE ratio of 159.91 and a beta of 1.60. Shire PLC has a 12-month low of $155.06 and a 12-month high of $209.22.
Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $3.73 earnings per share for the quarter, topping analysts’ consensus estimates of $3.53 by $0.20. The firm had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.73 billion. Shire PLC had a return on equity of 14.32% and a net margin of 4.70%. The business’s quarterly revenue was up 54.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.38 earnings per share. On average, equities research analysts predict that Shire PLC will post $14.88 earnings per share for the current fiscal year.
A number of equities analysts have recently weighed in on the company. BidaskClub lowered Shire PLC from a sell rating to a strong sell rating in a research note on Friday, June 16th. HSBC Holdings plc lowered Shire PLC from a hold rating to a reduce rating in a research note on Friday, May 19th. Royal Bank Of Canada reissued an outperform rating and set a $221.00 price target on shares of Shire PLC in a research note on Tuesday, April 18th. Sanford C. Bernstein lowered Shire PLC from an outperform rating to a market perform rating and dropped their price target for the company from $209.22 to $161.09 in a research note on Thursday, May 25th. Finally, Cantor Fitzgerald set a $222.00 price target on Shire PLC and gave the company a buy rating in a research note on Saturday, July 1st. Two analysts have rated the stock with a sell rating, six have given a hold rating and sixteen have given a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $223.18.
TRADEMARK VIOLATION WARNING: This article was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/05/shire-plc-nasdaqshpg-updates-fy17-earnings-guidance.html.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.